Johnson & Johnson (NYSE:JNJ) doesn't see an opening to make a deal with Actelion Ltd while the Swiss target is in acquisition talks with Johnson & Johnson (JNJ), according to a report from Bloomberg that cited Elias Zerhouni, the French drugmaker's global research and development president, as saying.